These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30365464)

  • 1. Everolimus and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Registry-based 10-year Follow-up of 5 Randomized Trials.
    Ying T; Wong G; Lim WH; Clayton P; Kanellis J; Pilmore H; Campbell S; O'Connell PJ; Russ G; Chadban S
    Transplantation; 2019 Aug; 103(8):1705-1713. PubMed ID: 30365464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study.
    Ying T; Wong G; Lim W; Kanellis J; Pilmore H; Campbell S; Masterson R; Walker R; O'Connell P; Russ G; Chadban S
    Am J Transplant; 2018 Dec; 18(12):2977-2986. PubMed ID: 29802791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial.
    Sommerer C; Budde K; Zeier M; Wüthrich RP; Reinke P; Eisenberger U; Mühlfeld A; Arns W; Stahl R; Heller K; Wolters HH; Suwelack B; Klehr HU; Hauser IA; Stangl M; Nadalin S; Dürr M; Porstner M; May C; Wimmer P; Witzke O; Lehner F
    Clin Nephrol; 2016 Apr; 85(4):215-25. PubMed ID: 26932178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
    Lim WH; Russ GR; Wong G; Pilmore H; Kanellis J; Chadban SJ
    Kidney Int; 2017 Apr; 91(4):954-963. PubMed ID: 28109543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.
    Budde K; Lehner F; Sommerer C; Reinke P; Arns W; Eisenberger U; Wüthrich RP; Mühlfeld A; Heller K; Porstner M; Veit J; Paulus EM; Witzke O;
    Am J Transplant; 2015 Jan; 15(1):119-28. PubMed ID: 25521535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients.
    Taber DJ; Chokkalingam A; Su Z; Self S; Miller D; Srinivas T
    Clin Transplant; 2019 Oct; 33(10):e13679. PubMed ID: 31365151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.
    Badve SV; Pascoe EM; Burke M; Clayton PA; Campbell SB; Hawley CM; Lim WH; McDonald SP; Wong G; Johnson DW
    Clin J Am Soc Nephrol; 2016 Oct; 11(10):1845-1855. PubMed ID: 27445164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 3-month, Multicenter, Randomized, Open-label Study to Evaluate the Impact on Wound Healing of the Early (vs Delayed) Introduction of Everolimus in De Novo Kidney Transplant Recipients, With a Follow-up Evaluation at 12 Months After Transplant (NEVERWOUND Study).
    Manzia TM; Carmellini M; Todeschini P; Secchi A; Sandrini S; Minetti E; Furian L; Spagnoletti G; Pisani F; Piredda GB; Cappelli G; Tisone G
    Transplantation; 2020 Feb; 104(2):374-386. PubMed ID: 31335776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial.
    de Sandes-Freitas TV; Pinheiro PMA; Sales MLMBO; Girão CM; Campos ÉF; Esmeraldo RM
    Transpl Int; 2018 Dec; 31(12):1345-1356. PubMed ID: 29969826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial.
    Krishnan A; Teixeira-Pinto A; Chan D; Chakera A; Dogra G; Boudville N; Irish A; Morgan K; Phillips J; Wong G; Lim WH
    Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28662279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
    Pascual J; Berger SP; Witzke O; Tedesco H; Mulgaonkar S; Qazi Y; Chadban S; Oppenheimer F; Sommerer C; Oberbauer R; Watarai Y; Legendre C; Citterio F; Henry M; Srinivas TR; Luo WL; Marti A; Bernhardt P; Vincenti F;
    J Am Soc Nephrol; 2018 Jul; 29(7):1979-1991. PubMed ID: 29752413
    [No Abstract]   [Full Text] [Related]  

  • 12. ABO blood group relationships to kidney transplant recipient and graft outcomes.
    Ng MSY; Ullah S; Wilson G; McDonald S; Sypek M; Mallett AJ
    PLoS One; 2020; 15(7):e0236396. PubMed ID: 32702043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients.
    Lim WH; Chang SH; Chadban SJ; Campbell SB; Dent H; Russ GR; McDonald SP
    Transplantation; 2009 Nov; 88(10):1208-13. PubMed ID: 19935375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial.
    Gullestad L; Eiskjaer H; Gustafsson F; Riise GC; Karason K; Dellgren G; Rådegran G; Hansson L; Gude E; Bjørtuft Ø; Jansson K; Schultz HH; Solbu D; Iversen M
    Transpl Int; 2016 Jul; 29(7):819-29. PubMed ID: 27067532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus in de novo liver transplant recipients: a systematic review.
    Tang CY; Shen A; Wei XF; Li QD; Liu R; Deng HJ; Wu YZ; Wu ZJ
    Hepatobiliary Pancreat Dis Int; 2015 Oct; 14(5):461-9. PubMed ID: 26459721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do patient characteristics influence efficacy and renal outcomes in liver transplant patients receiving everolimus?
    De Simone P; Saliba F; Dong G; Escrig C; Fischer L
    Clin Transplant; 2016 Mar; 30(3):279-88. PubMed ID: 26717035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
    Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials.
    Cooper M; Wiseman AC; Zibari G; McCague K; Kim Y; Geissler F; Nashan B
    Clin Transplant; 2013; 27(6):E625-35. PubMed ID: 24033455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.